A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC)
Clinical trial NCT07324876 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07324876
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-12-31
- Primary completion
- 2027-12-31
- Enrollment
- 860
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.